Comparison of Three Different Methods for Measurement of Cervical Cord Atrophy in Multiple Sclerosis

References

1. ↵
   Zivadinov R, Leist TP. Clinical-magnetic resonance imaging correlations in multiple sclerosis. J Neuroimaging 2005;15:10S–21S

   CrossRefPubMedWeb of Science
2. ↵
   Tench CR, Morgan PS, Jaspan T, et al. Spinal cord imaging in multiple sclerosis. J Neuroimaging 2005;15:94S–102S

   CrossRefPubMedWeb of Science
3. ↵
   Rocca MA, Hickman SJ, Bo L, et al. Imaging spinal cord damage in multiple sclerosis. J Neuroimaging 2005;15:297–304

   CrossRefPubMedWeb of Science
4. ↵
   Thorpe JW, Kidd D, Moseley IF, et al. Spinal MRI in patients with suspected multiple sclerosis and negative brain MRI. Brain 1996;119:709–14

   Abstract/FREE Full Text
5. ↵
   Kidd D, Thorpe JW, Kendall BE, et al. MRI dynamics of brain and spinal cord in progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;60:15–19

   Abstract/FREE Full Text
6. ↵
   Lycklama a Nijeholt GJ, Uitdehaag BM, Bergers E, et al. Spinal cord magnetic resonance imaging in suspected multiple sclerosis. Eur Radiol 2000;10:368–76

   CrossRefPubMed
7. ↵
   Rocca MA, Mastronardo G, Horsfield MA, et al. Comparison of three MR sequences for the detection of cervical cord lesions in patients with multiple sclerosis. AJNR Am J Neuroradiol 1999;20:1710–16

   Abstract/FREE Full Text
8. ↵
   Campi A, Pontesilli S, Gerevini S, et al. Comparison of MRI pulse sequences for investigation of lesions of the cervical spinal cord. Neuroradiology 2000;42:669–75

   CrossRefPubMed
9. ↵
   Nijeholt GJ, van Walderveen MA, Castelijns JA, et al. Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. Brain 1998;121:687–97

   Abstract/FREE Full Text
10. ↵
    Losseff NA, Miller DH. Measures of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry 1998;64 (suppl 1):S102–05

    PubMedWeb of Science
11. ↵
    Filippi M, Campi A, Martinelli V, et al. Brain and spinal cord MR in benign multiple sclerosis: a follow-up study. J Neurol Sci 1996;143:143–49

    CrossRefPubMedWeb of Science
12. ↵
    Lovas G, Szilagyi N, Majtenyi K, et al. Axonal changes in chronic demyelinated cervical spinal cord plaques. Brain 2000;123:308–17

    Abstract/FREE Full Text
13. ↵
    DeLuca GC, Ebers GC, Esiri MM. Axonal loss in multiple sclerosis: a pathological survey of the corticospinal and sensory tracts. Brain 2004;127:1009–18

    Abstract/FREE Full Text
14. ↵
    Davie CA, Barker GJ, Webb S, et al. Persistent functional deficit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995;118:1583–92

    Abstract/FREE Full Text
15. ↵
    Stevenson VL, Leary SM, Losseff NA, et al. Spinal cord atrophy and disability in MS: a longitudinal study. Neurology 1998;51:234–38

    Abstract/FREE Full Text
16. ↵
    Trapp BD, Peterson J, Ransohoff, RM, et al. Axonal transection in the lesions of multiple sclerosis. N Engl J Med 1998;338:278–85

    CrossRefPubMedWeb of Science
17. ↵
    Trop I, Bourgouin PM, Lapierre Y, et al. Multiple sclerosis of the spinal cord: diagnosis and follow-up with contrast-enhanced MR and correlation with clinical activity. AJNR Am J Neuroradiol 1998;19:1025–33

    Abstract
18. ↵
    Kidd D, Thorpe JW, Thompson AJ, et al. Spinal cord MRI using multi-array coils and fast spin echo. II. Findings in multiple sclerosis. Neurology 1993;43:2632–37

    Abstract/FREE Full Text
19. ↵
    Ingle GT, Stevenson VL, Miller DH, et al. Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain 2003;126:2528–36

    Abstract/FREE Full Text
20. ↵
    Lin X, Tench CR, Turner B, et al. Spinal cord atrophy and disability in multiple sclerosis over four years: application of a reproducible automated technique in monitoring disease progression in a cohort of the interferon beta-1a (Rebif) treatment trial. J Neurol Neurosurg Psychiatry 2003;74:1090–94

    Abstract/FREE Full Text
21. ↵
    Losseff NA, Webb SL, O’Riordan JI, et al. Spinal cord atrophy and disability in multiple sclerosis. A new reproducible and sensitive MRI method with potential to monitor disease progression. Brain 1996;119:701–08

    Abstract/FREE Full Text
22. ↵
    Lin X, Tench CR, Evangelou N, et al. Measurement of spinal cord atrophy in multiple sclerosis. J Neuroimaging 2004;14:S20–26

    CrossRefPubMedWeb of Science
23. ↵
    Coulon O, Hickman SJ, Parker GJ, et al. Quantification of spinal cord atrophy from magnetic resonance images via a B-spline active surface model. Magn Reson Med 2002;47:1176–85

    CrossRefPubMed
24. ↵
    McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001;50:121–27

    CrossRefPubMedWeb of Science
25. ↵
    Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–52

    Abstract/FREE Full Text
26. ↵
    Canny J. A computational approach to edge detection. IEEE Trans 1986 :679–98
27. ↵
    Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239–47

    Abstract/FREE Full Text
28. ↵
    Zivadinov R, Sepcic J, Nasuelli D, et al. A longitudinal study of brain atrophy and cognitive disturbances in the early phase of relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:773–80

    Abstract/FREE Full Text
29. ↵
    Benedict RH, Bruce J, Dwyer MG, et al. Diffusion-weighted imaging predicts cognitive impairment in multiple sclerosis. Mult Scler 2007;13:722–30

    Abstract/FREE Full Text
30. ↵
    Tavazzi E, Dwyer MG, Weinstock-Guttman B, et al. Quantitative diffusion weighted imaging measures in patients with multiple sclerosis. Neuroimage 2007;36:746–54

    CrossRefPubMedWeb of Science
31. ↵
    Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907–11

    Abstract/FREE Full Text
32. ↵
    Tench CR, Constantinescu CS. Technical Aspects of Spinal Cord Atrophy Measurement. Hauppauge, NY: Nova Biomedical Books;2004;63–72
33. ↵
    Stevenson VL, Miller DH, Leary SM, et al. One year follow up study of primary and transitional progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2000;68:713–18

    Abstract/FREE Full Text
34. ↵
    Rashid W, Davies GR, Chard DT, et al. Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study. J Neurol Neurosurg Psychiatry 2006;77:51–55

    Abstract/FREE Full Text
35. ↵
    Horakova D, Cox JL, Havrdova E, et al. Evolution of different MRI measures in patients with active relapsing-remitting multiple sclerosis over 2 and 5 years. A case control study. J Neurol Neurosurg Psychiatry 2007; [Epub ahead of print]
36. ↵
    Benedict R, Bruce J, Dwyer M, et al. Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis. Arch Neurol 2006;63:1301–06

    CrossRefPubMedWeb of Science
37. ↵
    Anderson VM, Fernando KT, Davies GR, et al. Cerebral atrophy measurement in clinically isolated syndromes and relapsing remitting multiple sclerosis: a comparison of registration-based methods. J Neuroimaging 2007;17:61–68

    CrossRefPubMedWeb of Science
38. ↵
    Rovaris M, Gass A, Bammer R, et al. Diffusion MRI in multiple sclerosis. Neurology 2005;65:1526–32

    Abstract/FREE Full Text
39. ↵
    Lin X, Blumhardt LD, Constantinescu CS. The relationship of brain and cervical cord volume to disability in clinical subtypes of multiple sclerosis: a three-dimensional MRI study. Acta Neurol Scand 2003;108:401–06

    CrossRefPubMedWeb of Science
40. ↵
    Bot JC, Barkhof F, Polman CH, et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 2004;62:226–33

    Abstract/FREE Full Text
41. ↵
    PRISMS Study Group and the University of British Columbia MS/MRI Analysis Group. PRISMS-4: Long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628–36

    Abstract/FREE Full Text
42. ↵
    Leary SM, Miller DH, Stevenson VL, et al. Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial. Neurology 2003;60:44–51

    Abstract/FREE Full Text
43. ↵
    Kalkers NF, Barkhof F, Bergers E, et al. The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. Mult Scler 2002;8:532–33

    Abstract/FREE Full Text